Unraveling Your Genome. Individualizing Radiation Therapy.TM

Cvergenx, Inc. is a genomic informatics company that provides decision-support to radiation oncologists to assist in radiation treatment planning.

Developed in collaboration with the Moffitt Cancer Center, Cvergenx uses a unique molecular signature to identify specific differences in tumor radiosensitivity. This novel discovery, central to the Company’s patented Radiosensitivity Index (RSI), provides radiation oncologists the first opportunity to adapt treatment and dose to genetic characteristics of specific tumors, and to personalize and optimize radiation treatment planning and therapy.